Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Narra J
Lestari, Nova D.
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
ACE inhibitors versus angiotensin receptor-neprilysin inhibitors for HFrEF management: A prospective cohort study from Indonesia Heriansyah, Teuku; Lestari, Nova D.; Hadi, Tjut F.; Novia, Rizki; Munawarah, Iffah; Taufiqurrahman, Taufiqurrahman; Yuvhendmindo, Shahcoga L.; Bashori, Ahmad A.
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.978

Abstract

Previous studies have reported that angiotensin receptor-neprilysin inhibitors (ARNI) are superior to angiotensin-converting enzyme inhibitors (ACEI) in treating heart failure with reduced ejection fraction (HFrEF). Unfortunately, previously published studies predominantly focused on Western populations, while the data remains insufficient in developing countries. The aim of this study was to compare the efficacies of ARNI and ACEI on patients with HFrEF in Indonesia. A prospective cohort study was conducted among heart failure patients at Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia. Both ACEI and ARNI each consisted of 40 subjects receiving standard treatment for heart failure. Left ventricular ejection fraction (LVEF), quality of life (QoL), suppression of tumorigenicity 2 (ST2), and troponin T were measured upon admission and at the end of the follow-up. In addition, the occurrence of major adverse cardiac events (MACE) was observed during 6 months of follow-up. Paired t-test was used to compare the outcomes of ACEI and ARNI. The results revealed that KKCQ score and LVEF were improved in both ARNI and ACEI groups (each with p<0.001). A higher KCCQ overall score was observed in the ARNI group in contrast to the ACEI group (p=0.01). ARNI demonstrated superior results in improving the ejection fraction as compared with ACEI (p=0.001). Troponin T and ST2 levels exhibited no significant difference between the two groups (p=0.07 and 0.286, respectively). MACE-associated mortality (p=0.696) and rehospitalization (p=0.955) were identical between both groups. In conclusion, ARNI was more efficacious than ACEI in improving the quality of life and left ventricular ejection fraction of patients with HFrEF. However, the efficacy was not significantly different in reducing the risk of MACE.
Enhancing neuromuscular recovery after sciatic nerve injury using stem cell therapy: Evidence from a preliminary preclinical study Firlana, Cut R.; Emril, Dessy R.; Dedy Syahrizal; Sartika, Cynthia R.; Lestari, Nova D.; Habibie, Yopie A.
Narra J Vol. 6 No. 1 (2026): April 2026
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v6i1.3018

Abstract

Sciatic nerve injury results in motor dysfunction and muscle atrophy, with limited effective therapies. Umbilical cord–derived mesenchymal stem cells (UC-MSCs) may promote neuromuscular recovery, but their effects on functional and muscle recovery remain unclear. This study aimed to evaluate the effects of UC-MSC therapy on functional and muscle recovery in an animal model of sciatic nerve injury. An animal experimental study with a post-test-only control group was conducted using adult male Wistar rats. Rats were randomly allocated into three groups: sham operation, saline control with sciatic nerve injury, and UC-MSC treatment after sciatic nerve injury. UC-MSCs were administered at a dose of 1×10⁶ cells/kg body weight immediately after nerve injury. Functional recovery was assessed using the extensor postural thrust (EPT) test, and muscle recovery was evaluated using the gastrocnemius muscle index (GMI) post 35 days of observation. Data were analyzed using one-way ANOVA for EPT percentage recovery and Kruskal–Wallis tests for GMI values, followed by post-hoc analysis. Our data indicated there was no significant EPT percentage recovery among the study groups. In contrast, relative gastrocnemius muscle mass was significantly different across groups (p=0.012), with post-hoc analysis demonstrating a significantly higher GMI in the UC-MSC group compared to the saline control group (109.75% vs 81.68%, p=0.003), indicating improved preservation of gastrocnemius muscle mass following UC-MSC therapy. This study highlights that UC-MSC therapy significantly improved gastrocnemius muscle preservation after sciatic nerve injury but did not result in detectable functional motor recovery at the observation time point. These findings suggest that UC-MSCs might exert early structural benefits that may precede functional recovery.
Enhancing neuromuscular recovery after sciatic nerve injury using stem cell therapy: Evidence from a preliminary preclinical study Firlana, Cut R.; Emril, Dessy R.; Dedy Syahrizal; Sartika, Cynthia R.; Lestari, Nova D.; Habibie, Yopie A.
Narra J Vol. 6 No. 1 (2026): April 2026
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v6i1.3018

Abstract

Sciatic nerve injury results in motor dysfunction and muscle atrophy, with limited effective therapies. Umbilical cord–derived mesenchymal stem cells (UC-MSCs) may promote neuromuscular recovery, but their effects on functional and muscle recovery remain unclear. This study aimed to evaluate the effects of UC-MSC therapy on functional and muscle recovery in an animal model of sciatic nerve injury. An animal experimental study with a post-test-only control group was conducted using adult male Wistar rats. Rats were randomly allocated into three groups: sham operation, saline control with sciatic nerve injury, and UC-MSC treatment after sciatic nerve injury. UC-MSCs were administered at a dose of 1×10⁶ cells/kg body weight immediately after nerve injury. Functional recovery was assessed using the extensor postural thrust (EPT) test, and muscle recovery was evaluated using the gastrocnemius muscle index (GMI) post 35 days of observation. Data were analyzed using one-way ANOVA for EPT percentage recovery and Kruskal–Wallis tests for GMI values, followed by post-hoc analysis. Our data indicated there was no significant EPT percentage recovery among the study groups. In contrast, relative gastrocnemius muscle mass was significantly different across groups (p=0.012), with post-hoc analysis demonstrating a significantly higher GMI in the UC-MSC group compared to the saline control group (109.75% vs 81.68%, p=0.003), indicating improved preservation of gastrocnemius muscle mass following UC-MSC therapy. This study highlights that UC-MSC therapy significantly improved gastrocnemius muscle preservation after sciatic nerve injury but did not result in detectable functional motor recovery at the observation time point. These findings suggest that UC-MSCs might exert early structural benefits that may precede functional recovery.
Co-Authors Bashori, Ahmad A. Cynthia R. Sartika Dedy Syahrizal Emril, Dessy R. Firlana, Cut R. Habibie, Yopie A. Hadi, Tjut F. Munawarah, Iffah novia, rizki Taufiqurrahman Taufiqurrahman Teuku Heriansyah, Teuku Yuvhendmindo, Shahcoga L.